Format

Send to

Choose Destination
Haematologica. 2014 Sep;99(9):1456-64. doi: 10.3324/haematol.2013.101386. Epub 2014 Jun 3.

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia.

Author information

1
Department of Hematology, Hemostasis, Oncology and Stem cell Transplantation, Hannover Medical School, Germany.
2
Department of Hematology, Oncology, and Tumor Immunology, Charité, Berlin, Germany.
3
Department of Molecular Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
4
Institute of Experimental Hematology, Hannover Medical School, Germany.
5
Division of Hematology and Oncology, University of Freiburg Medical Center, Germany.
6
Department of Internal Medicine III, University Hospital of Ulm, Germany.
7
Department of Cell Biology and Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
8
Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC, Canada Department of Medicine, University of British Columbia, Vancouver, BC, Canada.
9
Department of Hematology, Hemostasis, Oncology and Stem cell Transplantation, Hannover Medical School, Germany heuser.michael@mh-hannover.de.

Abstract

Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents. We found previously that the effect of decitabine on hematopoietic stem cell viability differed between Mll5 wild-type and null cells. We, therefore, investigated the role of MLL5 expression levels on outcome of acute myeloid leukemia patients who were treated with decitabine. MLL5 above the median expression level predicted longer overall survival independent of DNMT3A mutation status in bivariate analysis (median overall survival for high vs. low MLL5 expression 292 vs. 167 days; P=0.026). In patients who received three or more courses decitabine, high MLL5 expression and wild-type DNMT3A independently predicted improved overall survival (median overall survival for high vs. low MLL5 expression 468 vs. 243 days; P=0.012). In transformed murine cells, loss of Mll5 was associated with resistance to low-dose decitabine, less global DNA methylation in promoter regions, and reduced DNA demethylation upon decitabine treatment. Together, these data support our clinical observation of improved outcome in decitabine-treated patients who express MLL5 at high levels, and suggest a mechanistic role of MLL5 in the regulation of DNA methylation.

PMID:
24895338
PMCID:
PMC4562534
DOI:
10.3324/haematol.2013.101386
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center